Could a less frequent dose of a withdrawn myeloma drug bring new hope?

NCT ID NCT05874193

First seen Feb 05, 2026 · Last updated May 02, 2026 · Updated 9 times

Summary

This study tests whether giving belantamab mafodotin every 6 weeks instead of every 3 weeks is safer and still works for people with advanced multiple myeloma that has not responded to other treatments. The drug was previously pulled from the market after a confirmatory study failed, but some patients still benefited. The study will enroll 33 adults who have tried at least 4 prior therapies and will be treated in community clinics, not just large academic centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johnston Cancer Center

    Smithfield, North Carolina, 27577, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Johnston Hematology and Oncology of Clayton

    Clayton, North Carolina, 27570, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Maria Parham Hospital

    Henderson, North Carolina, 27536, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Scotland Health Care System

    Laurinburg, North Carolina, 28352, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UNC Health Southeastern

    Lumberton, North Carolina, 28358, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.